Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial

David A. Palma, Robert Olson, Stephen Harrow, +19

The Lancet

Open-label TrialRadiation TherapyMedicineOligometastatic CancersStereotactic Ablative Radiotherapy +5

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial

David A. Palma, Robert Olson, Stephen Harrow, +21

Journal of Clinical Oncology

Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis

Sashendra Senthi, Frank J. Lagerwaard, Cornelis J.A. Haasbeek, +2

The Lancet Oncology

Radiation TherapyMedicineCancer RecurrenceRetrospective AnalysisPathology +6

Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial

David A. Palma, Robert Olson, Stephen Harrow, +22

BMC Cancer

High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer

Kitty Huang, Sashendra Senthi, David A. Palma, +4

Radiotherapy and Oncology

Adaptive RadiotherapyMedical ImagingRadiation TherapyMedicineCancer Recurrence +8

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial

David A. Palma, Robert Olson, Stephen Harrow, +21

Surgical OncologyCancer ManagementOligometastatic CancersTreatment VerificationNeuro-oncology +18

Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial

Robert Olson, Lindsay Mathews, Mitchell Liu, +21

BMC Cancer

Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial

Robert Olson, Suresh Senan, Stephen Harrow, +19

International Journal of Radiation Oncology*Biology*Physics

Radiation MedicineLife OutcomesRadiation TherapyMedicineBrachytherapy +7

Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized Trial

Xiaotao Qu, Yujie Chen, Gregory S. Zaric, +15

International Journal of Radiation Oncology*Biology*Physics

Surgical OncologyOncologyHealth EconomicsCancer ManagementEconomic Analysis +9

Comparing rigid and deformable dose registration for high dose thoracic re-irradiation

Sashendra Senthi, Gwendolyn H.M.J. Griffioen, John R. van Sörnsen de Koste, +2

Radiotherapy and Oncology

Adaptive RadiotherapyRadiation MedicineRadiation TherapyMedical ImagingDeformable Dose Registration +8